GlassScriptPhysician profile
Candace Kapranos
NPI 1285265686
$5,195.57
in general payments reported to CMS, 2019-2025
23 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 93% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $724 · 2022: $925 · 2023: $1,029 · 2024: $925 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,546.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,089.06 | 2021-2025 | Cabenuva, Dovato, Rukobia |
| Abbvie INC. | $922.25 | 2021-2025 | |
| Paratek Pharmaceuticals, INC. | $823.22 | 2021-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $351.74 | 2021-2025 | Pifeltro, Zerbaxa, Dificid |
| Shionogi INC | $307.52 | 2021-2025 | Fetroja |
| Cumberland Pharmaceuticals, INC. | $305.13 | 2022-2025 | Vibativ |
| Melinta Therapeutics, LLC | $286.92 | 2024-2025 | Rezzayo, Kimyrsa |
| Gilead Sciences, INC. | $224.92 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $116.84 | 2025 | Rexulti |
| La Jolla Pharmaceutical Company | $102.76 | 2022-2023 | Xerava |
| E.R. Squibb & Sons, L.L.C. | $101.60 | 2025 | Cobenfy |
| Theratechnologies INC. | $99.37 | 2023-2025 | Egrifta, Trogarzo |
| Vyera Pharmaceuticals, LLC | $79.64 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $79.32 | 2025 | Vowst |
| Emd Serono, INC. | $58.91 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $52.56 | 2024-2025 | Rebyota |
| Insmed, INC. | $46.16 | 2021-2024 | Arikayce |
| Vanda Pharmaceuticals INC. | $34.86 | 2021 | |
| Janssen Biotech, INC. | $30.33 | 2021-2022 | |
| Astellas Pharma US INC | $23.61 | 2025 | Cresemba |
| Napo Pharmaceuticals INC | $20.11 | 2024 | Mytesi |
| Astrazeneca Pharmaceuticals LP | $19.78 | 2024 | Flumist Quadrivalent |
| Alexion Pharmaceuticals, INC. | $18.96 | 2024 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candace Kapranos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.